['hypercholesterolemia']
['placebo (for alirocumab)', 'alirocumab', 'lipid-modifying therapy (lmt)']

        Inclusion criteria:

        Participants with hypercholesterolemia and established coronary heart disease (CHD) or CHD
        risk equivalents who are not adequately controlled with a maximally tolerated daily dose of
        statin with or without other LMT, both at stable dose for at least 4 weeks prior to
        screening visit (Week -3).

        Exclusion criteria:

          -  Aged <18 years or legal age of adulthood, whichever was greater.

          -  Participants without established CHD or CHD risk equivalent.

          -  LDL-C <70 mg/dL (<1.81 mmol/L) in participants with a history of documented
             cardiovascular disease.

          -  LDL-C <100 mg/dL (<2.59 mmol/L) in participants without a history of documented
             cardiovascular disease.

          -  Not on a stable dose of LMT (including statin) for at least 4 weeks prior to the
             screening visit (Week -3) or between screening to randomization visits.

          -  Currently taking a statin other than atorvastatin, rosuvastatin or simvastatin.

          -  Atorvastatin, rosuvastatin or simvastatin was not taken daily or not taken at a
             registered dose.

          -  Daily doses above atorvastatin 80 mg, rosuvastatin 20 mg or simvastatin 40 mg.

          -  Fasting serum triglycerides >400 mg/dL (>4.52 mmol/L) at the screening period.

        The above information is not intended to contain all considerations relevant to a
        participants's potential participation in a clinical trial.
      